Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

ormation from the quarterly call by following the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our expected timelines for our SYNERGY and Borealis-1 trials. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 The New Jersey Patient Care and Access Coalition ... encourages men and their families to speak out to preserve ... Force (USPSTF) recommended healthy men should no longer receive prostate-specific ... This decision was made by a panel ...
... 2011 Masimo (NASDAQ: ... Japanese Ministry of Health Labor & Welfare (MHLW) ... rainbow® Acoustic Monitoring technology—providing noninvasive and continuous acoustic ... and enhance patient compliance.  Available for the first ...
Cached Medicine Technology:NJ Docs Say Cancer Detection Tool Saves Lives 2Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 2Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 3Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 4Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 5Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 6
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... discovery by Northwestern Medicine scientists could lead to potential ... in people with scleroderma. , Fibrosis, or scarring, ... of the skin and lungs can lead to serious ... concept for new therapeutic options centers on findings made ... who identified the role that a specific protein plays ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... Herley Industries, Inc. (Nasdaq: HRLY ) announced today ... contracts valued at approximately $4 million to provide various complex ... follow-on awards for an existing customer and program. The hardware ... , , Herley Industries, Inc. acquired Eyal Microwave Industries, ...
... before prescribing, researcher says , THURSDAY, June 4 (HealthDay ... the elderly, Swedish researchers say. , In their study, ... of suicides in older people. "Sedative treatment was associated ... the crude analysis and remained an independent risk factor ...
... London, New Delhi, Singapore and Washington DC (4 June, ... journal Palliative Medicine is to become the ... Formed in 1986, The Association for Palliative Medicine of ... doctors who work in hospices and specialist palliative care ...
... French . , Montreal, June 4th, 2009 ... a disease that results in severe breathing difficulty. According to ... worldwide. However the mechanisms responsible for some smokers developing COPD ... Dr.Manuel Cosio from the McGill University Health Centre, ...
... Frontiers in Labor and Employment Relations: Ensuring Good Jobs, ... , , , WASHINGTON, June 4 ... Employment Relations Association on June 11-12, 2009, features the ... on the auto crisis, top national experts on health ...
... The Usual With A Gift That Does Wonders For His ... , PACIFIC PALISADES, Calif., June 4 Forget ties ... he secretly desires but may not buy for himself: An ... hero. Dermagenics Physician-Formulated Anti-Wrinkle Moisturizer is an ...
Cached Medicine News:Health News:Herley's Israeli Subsidiary, GMI Eyal, is Selected to Provide Complex Microwave Switch Assemblies for a U.S. Customer 2Health News:Sedatives Increase Suicide Risk Among Elderly 2Health News:Investigation finds that cigarette smoking does not affect everyone in same way 2Health News:LERA National Policy Forum Set for June 11-12 in Washington, D.C. 2Health News:LERA National Policy Forum Set for June 11-12 in Washington, D.C. 3Health News:SHOW DAD YOU LOVE HIS FACE 2
... 1300 C is ideal for evaluating a wide ... parts of the body. Often referred to at ... magnetocardiography, gastrointestinal tract, fetal, spinal cord and peripheral ... C, with its 67 detector coils, covers a ...
... table configurations designed for a wide range ... capture 17 X 17 X-ray images from ... system includes a Bucky table, upright tilting ... suspended multi-positioning unit. Versatile and economical, the ...
... synthetic bone filler tailored for slow ... and Hydroxyapatite (HAP), its composition mimics ... the chemistry and microstructure of Bi-Ostetic ... provides optimal osteo-conduction. The spongy Bi-Ostetic ...
The TB Lead is a high quality bipolar intracardiac lead for cost effective temporary pacing and electrophysiology studies. The TB lead is available in sizes ranging from 4F to 6F and comes in either ...
Medicine Products: